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The chromosome passenger complex (CPC) is an essential regulator of mitosis
and cytokinesis. The CPC consists of Aurora B kinase, inner centromere protein
(INCENP), and the targeting subunits survivin and borealin/Dasra B. INCENP
is a scaffolding subunit for the CPC and activates Aurora B via its conserved
IN-box domain. We show that overexpression of soluble IN-box in HeLa cells
affects endogenous CPC localization and produces a significant increase in mul-
tinucleated and micronucleated cells consistent with CPC loss of function. The
dominant-negative effect of soluble IN-box expression depends on residues cor-
responding to hINCENP W845 and/or F881, suggesting that these are essential
for Aurora B binding in vivo. We then screened a targeted library of small (five
to nine residues long) circular peptide (CP) IN-box fragments generated using
split intein circular ligation of proteins and peptides (SICLOPPS) methodology.
We identified a number of CPs that caused modest but reproducible increases in
rates of multinucleated and micronucleated cells. Our results provide proof of
concept that inhibition of the Aurora B–IN-box interaction is a viable strategy
for interfering with CPC function in vivo.2. Introduction
The chromosomal passenger complex (CPC), which consists of Aurora B kinase
and the three non-enzymatic subunits inner centromere protein (INCENP) [1],
survivin [2,3] and borealin/Dasra-B [4,5] orchestrates key events during mitosis
[6]. INCENP acts as a scaffold for the CPC and also activates Aurora B. The
INCENP N-terminus interacts with CPC targeting subunits survivin and borea-
lin in a three-helix bundle [7]. INCENP also interacts directly with chromatin
and the mitotic spindle via interactions with heterochromatin protein 1 (HP1)
[8] and microtubules [2].
The C-terminus of INCENP contains the IN-box domain, which binds and
activates Aurora B [9–13]. Upon INCENP binding, Aurora B phosphorylates a
conserved threonine–serine–serine (TSS) motif located near the C-terminus of
the IN-box [12,13]. This promotesCPC clustering, leading to transphosphorylation
of threonine 232 on the Aurora B activation loop and full kinase activation [14].
Aurora B is a member of a conserved family of serine/threonine kinases that,
in vertebrates, contains a further two paralogues: Aurora A and C. Aurora A has
key roles in mitotic entry, centrosome maturation and spindle organization [15],
whereas Aurora C is essential for gametogenesis and appears to function in early
embryogenesis rather than in somatic cells [16–19]. Because of their role in pro-
moting accurate cell division, the Aurora kinases have been actively explored as
targets for chemical inhibition in the treatment of cancer [20,21].
Aurora inhibitors constructed to date have all been designed to interfere
with the activity of the ATP-binding pocket. Several relatively specific inhibitors
have been obtained, including hesperadin, ZM447439 and AZD1152 [22–24].
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many other kinases [25], these small molecules also exhibit
off-target activity against a number of other kinases. Further-
more, it is relatively straightforward to isolate Aurora B
mutants resistant to the inhibitors [26,27], and the utility of
these compounds in the clinic may therefore be limited.
In this study, we have explored an alternative strategy for
the inhibition of the CPC. As the interaction between
INCENP and Aurora B is essential for activation and localiz-
ation of the kinase, we have investigated the use of peptides
and cyclic peptides to disrupt this interaction.We used success-
ful completion of cytokinesis as a read-out for CPC activity, as
even a small decrease in Aurora B activity impairs this process.
Mild CPC hypomorphs capable of rescuing chromosomal
alignment and other defects associated with CPC loss of func-
tion are unable to support normal cytokinesis in animal cells
[28]. We find that a 75 aa peptide comprising most of the
IN-box strongly interferes with CPC function in vivo. Further
dissection of the interaction using short cyclic peptides yielded
very modest but reproducible inhibitors of CPC function.a-tubulin
55
40
Figure 1. Expression and processing of SICLOPPS in HeLa cells. (a) Translation
of SICLOPPS constructs produces a linear precursor that undergoes post-
translational splicing to yield a linear product and a circularized peptide or
protein (adapted from [30]). (b) Experimental timeline for testing SICLOPPS
expression by transient transfection in this study. (c) Immunoblot detection
of the SICLOPPS linear precursor (P) and the faster migrating linear product (L).3. Results
3.1. Expression and processing of SICLOPPS constructs
in HeLa cells
For the purpose of this study, we wished to genetically
express the hINCENP IN-box domain and smaller fragments
thereof as soluble peptides in vivo. As small, unmodified pep-
tides tend to be unstable in cells, we sought to stabilize
putative inhibitory peptides via head-to-tail circularization
using split intein circular ligation of protein and peptides
(SICLOPPS) [29]. This approach relies on the in-frame inser-
tion of a nucleotide sequence encoding the desired protein
or peptide as a linker between two halves of a split intein.
The two halves of the split intein are oriented so that their
post-translational splicing in cis leads to the excision of the
linker region as a cyclic peptide (CP; figure 1a).
We opted to the use the naturally split DnaE intein from the
cyanobacterium Synechocystis species PCC6803 (Ssp) [31]
because it has been used in previous SICLOPPS library appli-
cations in prokaryotes and lower eukaryotes (e.g. [32,33]).
As the Ssp DnaE intein had not previously been shown to
circularlize peptides in human cells, we first assessed the
expression and processing of a 3xmyc-tagged Ssp DnaE
SICLOPPS test construct.
For an initial test of the system, we transiently transfected
HeLa cells with a construct expressing myc-tagged Ssp DnaE
SICLOPPS with the linker peptide ‘CFGGSGGHPQFANA’,
enriched for transfected cells by puromycin selection and exam-
ined whole cell lysates by immunoblotting to verify SICLOPPS
construct expression and processing (figure 1b,c). At 48 h post-
transfection, we could readily identify bands corresponding to
the precursor and the faster migrating linear product. We note
that throughout this study, we have not directly detected the
cyclic peptides expressed in cells as the low abundance of
these products often precludes their detection. However, based
on a published study employing the Ssp DnaE intein for in vivo
circular ligation in eukaryotes, detection of the linear product
of intein splicing is a reliable reporter of cyclization [33].
In control experiments, cells were transfected with a con-
struct expressing a double mutant version of the construct inwhich residues corresponding to T69 and H72 within the
N-terminal Ssp DnaE intein were substituted with alanines
(hereby referred to as SICLOPPSAA). These mutations have
been previously shown to abolish splicing [34]. Indeed,
only the precursor band was detected in lysates from cells
expressing SICLOPPSAA (figure 1c).
Together, these results demonstrate that the SspDnaE intein
is readily expressed inHeLa cells and undergoes processing in a
manner consistent with CP production.3.2. Dominant-negative effect of the soluble INCENP
IN-box
In order to explore the consequences of inhibiting the Aurora
B–IN-box interaction in vivo in HeLa cells, we expressed a
soluble 75 amino acid hINCENP fragment spanning residues
825–894, which contains the IN-box. The location of the
Aurora B-IN-box interface relative to the whole CPC is out-
lined in figure 2a. This IN-box fragment was inserted as a
linker in the SICLOPPS construct and flanked with native
Ssp DnaE extein residues in an attempt to enhance processing
(figure 2b). As a control, we also expressed the Aurora B
D218N kinase-dead mutant (hereby referred to as Aurora
BKD), which has previously been shown to have a strong
dominant-negative effect on CPC function [35]. Overexpres-
sion of Aurora BKD had a very pronounced effect, eliciting
an approximately 20-fold increase in the fraction of cells
with abnormal nuclei (i.e. multinucleate and micronucleate
cells; figure 2c,d ). This increase in the abnormal nuclei frac-
tion (ANF) was highly significant (p, 0.001, n ¼ 3, x2-test).
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Figure 2. Soluble IN-box expression impairs CPC function. (a) Representation of the CPC highlighting the location of the IN-box (adapted from [6]). (b) Sequence of
the soluble IN-box fragment inserted into the SICLOPPS construct containing IN-box residues (green) flanked by native Ssp DnaE extein residues (black). Boxed
regions indicate location of mutations made to yield IN-boxW845G, IN-boxF881A, IN-boxdbl and IN-boxAAA constructs. (c) Representative micrographs of DAPI and
rhodamine phalloidin-stained puromycin-selected cells transiently expressing soluble IN-boxWT constructs for 48 h. Dotted outlines indicate cells with nuclear mor-
phological aberrations. (d ) Quantification of abnormal nuclei frequency (ANF) in the same samples as the previous panel as well as for an Aurora B kinase-dead
control. (e) Quantitative western blot detection of the SICLOPPS linear precursor (P) and the faster migrating linear product (L) in samples treated as in (c). Unspecific
bands are marked with an asterisk. ( f ) Quantification of the ANF elicited by SICLOPPSAA IN-box mutant constructs under identical conditions to those outlined in (c).
( for (c) and ( f ): n ¼ 3; more than 1000 cells per replicate; error bars: +s.e.m.; *** indicates a significance of p, 0.001 between the sample and empty vector
control as determined using the x2-test).
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expressing SICLOPPS IN-boxWT for 48 h also revealed a sub-
stantial increase in ANF, namely fivefold that of an empty
vector control ( p, 0.001, n ¼ 3, x2-test; figure 2c,d ). Quanti-
tative immunoblotting analysis revealed that 34% of theSICLOPPS IN-boxWT translation product was processed to
yield the mature ligated extein, which is expected to correlate
with IN-boxWT CP production (figure 2e). This dominant-
negative effect was not due to the presence of the Ssp DnaE
intein fragments. Under the same conditions, the SICLOPPS
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homology to the IN-box—had no effect on CPC function
irrespective of their processing competency (figure 2d ).
Asprocessingof the SICLOPPS IN-boxWT constructwas only
of limited efficiency, this raised the question of whether the
inhibition of CPC activity was due to the cyclic peptide,
the linear precursor form or both. To distinguish between these
possibilities, we constructed a processing-deficient version
of the SICLOPPS IN-boxWT construct. When SICLOPPSAA
IN-boxWT was expressed in HeLa cells, it had an even more
pronounced effect than the processing proficient SICLOPPS
IN-boxWT construct (figure 2c,d). Interestingly, the mutant
construct was approximately 35% more active at inhibiting
the CPC than thewild-type construct, approximately equivalent
to the processing efficiency of the wild-type construct. This
suggests that the linear intein-flanked processing precursor
may be responsible for inhibiting the CPC, rather than the
circularized IN-box.
These experiments suggest that disruption of INCENP
binding to Aurora B can effectively inhibit CPC activity,
even in the presence of the endogenous wild-type proteins.
3.3. hINCENP W845 and F881, but not the TSS motif,
are required for IN-box inhibition of CPC function
in vivo
Although the most likely explanation of the inhibitory effect
of the SICLOPPS and SICLOPPSAA IN-boxWT constructs is
that the IN-box fragment binds to Aurora B and displaces
endogenous INCENP, other possibilities cannot be excluded.
We, therefore, examined the effect of mutations in the IN-box
that have previously been shown to interfere with INCENP
binding to and/or activation of Aurora B. These mutants
were introduced into the SICLOPPSAA processing-deficient
construct, as this gave the most robust inhibition of CPC
function in our ANF assay.
Previous work had shown that mutation of the highly con-
served residue equivalent to hINCENP W845 abolished the
ability of INCENP to bind to Aurora B, and that this mutant
form of INCENP could not support cell viability in DT40 cells
[28]. Structural analysis of a Xenopus IN-box fragment bound
to Aurora B predicted that this tryptophan was a critical deter-
minant for the interaction between the two proteins [36]. In
support of this, expression of SICLOPPSAA IN-boxW845G in
HeLa cells had no deleterious effect on CPC function in our
assay (figure 2f). This strongly supports the notion that solu-
ble IN-box inhibition of the CPC involves disruption of the
interaction between endogenous INCENP and Aurora B.
Structural analyses had identified a second INCENP resi-
due, corresponding to hINCENP F881, as likely to be essential
for activation of the kinase [36]. A previous study had shown
that truncated hINCENP lacking the region surrounding F881
could efficiently pull down Aurora B, albeit inactive, from cell
lysates when these were coexpressed in Sf-9 cells [13]. Sub-
sequent work in chicken DT40 cells showed that indeed an
INCENP mutant lacking the corresponding phenylalanine
could pull down Aurora B but could not rescue viability in the
absence of wild-type INCENP [28]. Interestingly, expression
of SICLOPPSAA IN-boxF881A in HeLa calls also had no deleter-
ious effect on CPC function (figure 2f). This suggests that, in
the context of this IN-box fragment, F881 is required for binding
of INCENP to Aurora B with sufficient affinity to interfere withbinding of the endogenous proteins. As expected, a double
mutant containing both mutations, SICLOPPS IN-boxW845G/
IN-boxF881A (referred to as SICLOPPSAA IN-boxdbl) also had
no inhibitory effect on CPC activity (figure 2f ).
The C-terminal region of the IN-box contains a
threonine–serine–serine (TSS) motif that is phosphorylated
by Aurora B and is required for the full activation of the
kinase [12,13,37]. SICLOPPSAA IN-boxAAA constructs in
which the TSS motif was substituted with a stretch of ala-
nines elicited a strong increase in ANF indistinguishable
from the IN-boxWT constructs (figure 2f ). This result suggests
that the TSS motif is dispensable for Aurora B binding in vivo,
consistent with previous observations [13,37].
3.4. Soluble IN-box causes the mislocalization of the
CPC in mitosis
As INCENP is involved in both the activation and localization
of the CPC during mitosis, we predicted that if soluble IN-box
constructs disrupt the association of INCENP with Aurora B,
then the localization of the kinase should be perturbed in vivo.
To test this hypothesis, we examined the effect of expressing
SICLOPPSAA IN-boxWT and IN-boxdbl, or an empty vector
control, on the localization of Aurora B in mitotic HeLa cells.
Consistent with the hypothesis, the localization of Aurora B
in mitotic cells was abnormal in cells expressing SICLOPPSAA
IN-boxWT, but not IN-boxdbl, when examined by immunofluor-
escence at 48 h post-transfection (figure 3a). Compared with
control cells transfected with an empty vector, the localization
of Aurora B was significantly affected in all stages of mitosis in
cells transfected with IN-boxWT but not IN-boxdbl (p, 0.001
and p. 0.05, respectively, n¼ 3, Fisher’s exact test; figure 3b).
In the presence of IN-boxWT, Aurora B was either completely
or partially mislocalized in the vast majority of cells fixed in pro-
phase to anaphase (figure 3b). The localization of Aurora B in
cells in telophase or undergoing cytokinesis was less severely
affected by IN-boxWT expression and normal localization could
be observed in roughly half the cells scored. The appreciable
drop in the severity of mislocalization in these later phases
may be due to the use of transiently transfected constructs.
That is, cells with lower soluble IN-box levels, which would
occur owing to expression heterogeneity, may be less severely
affected in both CPC localization and mitotic progression.
Interestingly, although cell samples each transfected
with one of the three constructs had comparable mitotic
indexes (empty vector: 4.3% +0.6, IN-boxWT 4.3% +0.7,
IN-boxdbl 4.0% +1.5) cells expressing the SICLOPPSAA
IN-boxWT construct exhibited a significant increase in pro-
metaphase cells relative to the empty vector control ( p,
0.001, n ¼ 3, x2-test; figure 3c). This increase in the number
of cells in prometaphase suggests a chromosome alignment,
but not mitotic checkpoint, defect.
In summary, the data presented thus far support a model
where disruption of the interaction between INCENP and
Aurora B is able to significantly interfere with CPC function
in vivo.
3.5. INCENP IN-box cyclic peptide library screen
The Aurora B–IN-box interaction occupies an extended inter-
face analogous to a crown on the small lobe of the kinase
[36,38]. Although we are able to disrupt this interaction using
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Figure 3. Soluble IN-box expression causes Aurora B mislocalization. (a) Representative micrographs showing the localization of Aurora B in puromycin-selected
mitotic HeLa cells transiently transfected with either SICLOPPSAA IN-boxWT or an empty vector control 48 h after transfection. DNA, the mitotic spindle and cen-
tromeres were detected using DAPI, anti-tubulin and ACA, respectively. (b) Quantification of Aurora B mislocalization during mitotic phases and cytokinesis in
samples treated as in the previous two panels. (n ¼ 3; more than 100 cells per replicate). Cells in which Aurora B was clearly visible in the cellular region matching
canonical CPC localization [1] were scored as ‘normal’. Faint Aurora B accumulation in the correct region was scored as ‘partial’, as was clear signal only present in
part of the region where it should be expected. All other cells were scored as ‘mislocalized’. Coloured boxes have been added around the merged images in panel A
to show how these representative cells would be scored. (c) Distribution of cells in different stages of mitosis and cytokinesis in puromycin-selected HeLa cells
transiently expressing SICLOPPSAA IN-box constructs for 48 h. (n ¼ 3; more than 100 cells per replicate; error bars: +s.e.m.; *** indicates a significance of
p, 0.001 between the sample and empty vector control).
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 on May 26, 2015http://rsob.royalsocietypublishing.org/Downloaded from a 75 amino acid residue construct, this is far from the short pep-
tide interaction motifs that are typical starting points for the
development of peptidomimetic small molecules.We therefore
wished to explore whether smaller IN-box fragments could
also dissociate the Aurora B–IN-box interaction.
Todo this,we generated andassayed a libraryof circularized
IN-box fragments ranging from four to eight residues. Each
cyclic peptide also contained an invariable cysteine residue,
derived from positionþ1 of the native extein, which is required
for SspDnaE inteinprocessing [39]. Thus, the library consisted of
cyclic peptides ranging from pentamers to nonamers.
To focus on IN-box residues most closely associated with
the Aurora B N-terminal lobe, the library was designed toencompass INCENP residues 834–894—the region of the
IN-box homologous to that used by Sessa et al., in their struc-
tural study of the Aurora B–IN-box complex [36] (figure 4a).
The core library spanning this region consisted of octamers
(seven variable residues plus the invariant cysteine). As we
had shown that W845 and F881 are essential for IN-box bind-
ing to Aurora B, sub-libraries containing a range of cyclic
peptide sizes were generated centered on those residues.
Our intent in generating a range of cyclic peptides with simi-
lar sequences but different sizes was to vary the degree of
conformational constraint on a given epitope. The core library
and sub-libraries were designed so that adjacent constructs
were offset by a single amino acid residue. The full library
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Figure 5. (a) Reproducibility and processing dependency of the hits ident-
ified in the initial screen. Reproducibility indicates that, when assayed in
triplicate, the ANF increase elicited by a given processing-competent SICLOPPS
construct was significantly different from that of an empty vector control
( p , 0.05, n ¼ 3, Mann–Whitney U test). Processing dependency means
that the SICLOPPSAA did not have a significant effect on ANF increase relative
to the same control ( p. 0.05, n ¼ 3, Mann–Whitney U test). (b) ANF
increase of the SICLOPPSWT and SICLOPPSAA versions of reproducible and pro-
cessing dependent library constructs (n  3; error bars: +s.e.m.; *, ** and
*** indicate a significances of p , 0.05, ,0.01 and ,0.001, respectively,
between the sample and empty vector control using Mann–Whitney U test).
(c) Quantitative western blot detection of SICLOPPS processing in selected
processing-competent library constructs. The extent of processing, indicated
beneath each lane, is a measure of linear product (L) band intensity divided
by the sum of the product and the precursor (P) bands. (d ) Correlation
between the extent of processing and the ANF elicited of selected IN-box
library constructs, as measured by quantitative western blotting and
fluorescence microscopy, respectively.
rsob.royalsocietypublishing.org
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cloned in the SICLOPPS expression vector. The library pep-
tide sequences can be found in electronic supplementary
material, table S1.
The IN-box library was screened using the same ANF
microscopy assay as the soluble IN-box constructs. A two-
step strategy was used: a rapid first pass screen was used to
screen out constructs with little or no effect, then the remaining
candidate peptides were assayed in greater depth. In the first
pass, the full librarywas screened twice independently. To nor-
malize against any slight variation in ANF that might occur
over successive cell passages, in each case, we compared the
ANF increase of a construct relative to an empty vector control
assayed in parallel, rather than rawANF values. Constructs eli-
citing an average ANF increase greater than 2 standard
deviations from that of the full set of empty vector control
samples were carried forward into the next step. This cut-off
criterion was met by 20 of the 94 library members (figure 4b).
No constructs caused an average decrease in ANF greater
than 2 standard deviations from the same control.
The initial hit constructs were then assayed in triplicate to
verify whether their effects on ANF were reproducible, and
whether their dominant-negative effect relied on peptide cycli-
zation. Upon rescreening, 14 of the 20 initial hit constructs were
found to produce reproducible effects (figure 5a). To test the
cyclization dependency, putative hit constructs were assayed
in parallel with matched processing-deficient SICLOPPSAA
mutants. Validated constructs whose matched SICLOPPSAA
version did not elicit a significant ANF increase relative to
the empty vector control were deemed to be cyclization depen-
dent. In these experiments, 4 of the 14 confirmed hit constructs
were shown to require cyclization to produce their effect
on ANF (figure 5a). Thus, the other 10 constructs appear to
exert their effects as peptide aptamers, analogous to the
SICLOPPSAA IN-box construct.
Perhaps disappointingly, the strength of the inhibition
observed for all constructs was modest. Although all peptides
classified as ‘hits’ exhibited an ANF increase reproducibly over
2 standard deviations above the mean seen with the empty
vector control, the maximum effect observed was an elevation
of only 1.7 (figure 5b). For comparison, the SICLOPPSAA
IN-boxWT construct, caused an ANF of approximately 30%
(figure 2d). This 7 ANF increase corresponds to greater
than 38 standard deviations above the mean seen with the
empty vector control (figure 5b).
We also wished to determine whether the magnitude of
the observed effects on ANF depended on the efficiency of
intein processing. In addition to the absolute requirement for
a nucleophilic residue in extein position þ1 [39], the efficiency
of Ssp DnaE intein processing can also be modulated by other
extein residues [40]. By definition, as we scanned across the
IN-box sequence within the library, the residues present
within the linker vary widely. To test whether there was a
link between peptide activity and processing, a random
sample of hit and non-hit peptides was assayed for processing
efficiency andANF increase in parallel (figure 5c,d). Processing
efficiency was found to range between 1 and 99% (mean ¼
36.1%, s.d. ¼ 28.36). No correlation was detected between
SICLOPPS processing rates and peptide activity (Pearson’s
r ¼ 20.11; p ¼ 0.54; n ¼ 35). This lack of correlation indicates
that processing alone does not determine a construct’s activity,
suggesting that activity is dependent on the construct
sequence. This observed heterogeneity of processing renders
rsob.roy
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of the activities of different hit peptides, or of to compare the
activities of hit peptides against scrambled versions thereof
using SICLOPPS methodology.alsocietypublishing.org
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These experiments show that disruption of the interaction
between INCENP and Aurora B is a viable strategy for inter-
fering with CPC function in cells. Of the two strategies
explored here—using linear protein fragments and using
cyclic peptides—the former option appears to be more effec-
tive at inhibiting the CPC. This is probably not solely due to
the approximately 10 longer soluble IN-box peptide used
compared with the constructs in our SICLOPPS library
screen, as the circularized version of the longer (75 aa)
IN-box peptide also appeared to be less efficient at inhibition
the CPC than its linear counterpart.
Examination of the IN-box–Aurora B crystal structure
suggests an obvious explanation for this effect [36,38]. In
that structure, the IN-box encircles the small lobe of the
kinase like a crown. If interactions around the perimeter of
the small lobe can contribute to stabilizing the INCENP–
Aurora B interaction, then it may well be that a linear peptide
that can wind around the surface of the small lobe will be
more efficient than a circular molecule which, in the case of
our 75aa IN-box fragment would have to thread itself over
the lobe to bind correctly and displace endogenous INCENP.
The failure of our cyclic peptide screen to identify strong
inhibitors of the INCENP–Aurora B interaction may also be
explained by the extended interaction surface seen in the crystal
structure. For a small cyclic peptide to block INCENP binding,
the peptide would have to occupy a localized high affinity site
that is not readily displaced by the more extended endogenous
polypeptide. Given that the single amino acid changes W845G
andF881Acan block INCENPbinding toAurora B, it seemed in
principle possible that short high affinity peptides might dis-
place the endogenous protein, but we did not find such
peptides in our library. We note that, in contrast to the soluble
IN-box, we found a small number of constructs that were
more active in their processing-competent (i.e. SICLOPPSWT)
forms. The IN-box–Aurora B interaction may be more accessi-
ble to smaller conformationally constrained probes. It is also
possible that the bound intein moieties in the unprocessed con-
structs could in some cases interfere with the binding of shorter
peptides such as those present in the library. Nevertheless, our
cyclic peptide screen helps to establish parameters for future
similar screens against Aurora B and other targets. We suggest,
however, that in such screens, it may be more fruitful to target
protein–protein interactionswith less topologically constrained
probes, provided that they are sufficiently stable in vivo.
The approach used here—probing the INCENP–Aurora B
interaction using genetically encoded circular peptides—has
several advantages over the alternative of chemically synthe-
sizing cyclic peptides that can only be added exogenously to
cells. Firstly, the chemical synthesis of such circular peptides
is not routine, and is costly, particularly for the large numbers
of cyclic peptides needed for library-scale screens. Secondly,
once synthesized, such peptides are likely to have extremely
variable solubility properties, given local variations in protein
sequence. Thus, libraries of peptides are likely to require a var-
iety of solubilization conditions, some of whichmay be toxic tocells. Thirdly, even when they are solubilized, it may be diffi-
cult to find a reproducible method for introducing the
peptides into target cells.
On the other hand, our analysis has revealed a number of
difficulties with the genetic encoding of cyclic peptides by the
SICLOPPS strategy, in addition to the topological problems
with circular peptides discussed above. Of these, perhaps
the most significant is that of intein processing heterogeneity.
Assessment of processing efficiencies within the library
revealed extensive variability. Thus, despite the convenience
of SICLOPPS for generating and delivering CP libraries,
this processing heterogeneity of Ssp DnaE derived constructs
limited the further assessment of our validated hits. For
example, it isnot clear how to conduct side-by-side comparisons
of the effectiveness of pairs of cyclic peptides (e.g.wild-type and
scrambled/mutant version) that are expressed and/or pro-
cessed to different extents. This, coupled with the relatively
low potency, led us to forego testing whether the activity of
cyclization-dependent validated hit peptides containing resi-
dues W845 and F881 depended on those residues, as it did in
the case of the full length IN-box construct. Furthermore, the
average processing efficiency of the constructs assayed
tended to be low. The effective size of our IN-box library in
terms of effectively produced CPs may therefore have been
smaller than anticipated. That a portion of constructs within
a combinatorial SICLOPPS library will not be processed effi-
ciently should also be taken into account when estimating
the effective size and complexity of such libraries.
The dominant-negative effect of the soluble IN-box on CPC
function is likely to be achieved by its interfering with the
INCENP–Aurora B interaction. Our results therefore suggest
that the INCENP–Aurora B interaction is a suitable target for
an inhibitor approach. As demonstrated in earlier chicken
DT40 INCENP knockout/replacement experiments, even a
mild drop in CPC function is incompatible with cell prolifer-
ation and survival [37]. Thus, disrupting the Aurora B–IN-
box interaction appears to be incompatible with cell survival.
The dominant-negative effect of the IN-box domain was
similar but less pronounced than that of the Aurora B
kinase-dead mutant. In both instances, endogenous Aurora
B, which possesses basal activity, should be present in the
cells. However, kinase-dead Aurora B might not only compete
with endogenous Aurora B for binding to INCENP, but might
also act as a competitive inhibitor by making non-productive
binding interactions with potential substrates.
Bymutagenizing the soluble IN-box construct,wewere able
to begin to map the structural requirements for its dominant-
negative effect on CPC function. These requirements are likely
to be similar as those for IN-box binding to Aurora B in vivo.
Our findings that hINCENP W845 is necessary for the domi-
nant-negative effect, and conversely that the TSS motif is
dispensable, are in agreement with previously published obser-
vations on the IN-box–Aurora B interaction. Surprisingly,
hINCENP F881 was also required for the INCENP fragment
to interfere with CPC function in HeLa cells. Mutation of the
equivalent INCENP residue to alanine in chicken DT40 cells
still permits INCENP binding to Aurora B [28] and a construct
lacking this residue can also pull down Aurora B in vitro [13].
Thus, the functional assay employed here appears to have
greater sensitivity than conventional binding studies.
In summary, our results indicate that blocking the Aurora
B–IN-box interaction could be a viable alternative to ATP-
competitive inhibitors for Aurora B inhibition. The surfaces
rsob
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and F881 may represent the most promising target sites for
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5.1. Tissue culture
HeLa Kyoto cells were maintained in Dulbecco’s modified
Eagle medium (Life Technologies) supplemented with 1% fetal
bovine serum (SIGMA) and 1 penicillin/streptomycin (Life
Technologies) at 378C (5.0% CO2), and passaged as required.
5.2. Plasmids and transient transfection
All plasmids used in this study were generated in the
pIRESpuro2 vector (Clontech). A synthetic C-terminally
3xmyc-tagged Ssp sp. PCC6803 DnaE-based SICLOPPS ORF
containing the insert CFGGSGGHPQFANA was custom syn-
thesized by DNA2.0 (Menlo Park, CA, USA).
5.3. Antibodies
The following primary antibodies and dilutions were used
for immunofluorescence: 1 : 500 rabbit polyclonal anti-Aurora B
ab2254 (Abcam); 1 : 200 sheeppolyclonal anti-alpha/beta tubulin
ATNO2 (Cytoskeleton, Inc.); 1 : 200 human anti-centromere
antibody (ACA; [41]). For western blotting, 1 : 15 000 mouse
monoclonal B512 anti-aTubulin (SIGMA) and 1 : 1000
mouse monoclonal anti-Myc 9E10 (Covance) were used.
5.4. SICLOPPS IN-box library
The INCENP IN-box library was created in a modified version
of pIRES puro2 vector from which the multiple cloning site
(MCS) AflII site was removed by site-directed mutagenesis
(oligos: 50-CCGGTTAACAGGCCTATAGCGCTAGCTAGGC
CGC-30 and 50-GCGGCCTAGCTAGCGCTATAGGCCTGTT
AACCGG-30).HPLC-purifiedoligosencodingeachof the library
members were purchased from Sigma-Aldrich (St Louis, MO,
USA) and used to generate individual library inserts using
the polymerase chain reaction (PCR) protocol described pre-
viously, but with the omission of the zipper step [30]. Inserts
were amplified using the Expand High Fidelity PCR System
(Roche) from a NcoI-digested pIRES puro2 SICLOPPSWT
template using a universal forward primer (50-CCGAATTCGG
ATCCATGGTTAAAGTAATCGGC-30) annealing to the MCS
and a reverse primer (50-GCCCGTATTCAACTGTAAGTATTT
CAGTGCCAAAACTTAAGCA[variable]GCAATTATGGGCA
ATAGCC-30) encoding the library insert, which spans the junc-
tion between the two intein halves and a AflII site present
within the distal intein half. Library member amino acid
sequences and primer nucleotide sequences are listed in elec-
tronic supplementary material, table S1. Library inserts were
cloned into pIRES puro2 SICLOPPSWT using BamHI andAflII. For transfection, library constructs were prepared using
the transfection-grade Plasmid Mini Kit (QIAGEN) following
the manufacturer’s instructions. Protein-splicing deficient
SICLOPPSAA mutants of selected library constructs were gen-
erated by digestion with BamHI and AflII and insertion of the
resulting fragment into pIRES puro2 SICLOPPSAA, which
also lacks the MCS AflII site.
5.5. CPC function and SICLOPPS processing assays
HeLaKyoto cellswere seeded to a density of 5  104 perwell in
6-well plates containing uncoated 16 mmglass coverslips. Two
days post-seeding, wells were transfectedwith 2 mg of plasmid
using 6 ml X-tremeGENE 9 (Roche) following manufacturer’s
instructions. Twenty-four hours post-transfection, growth
medium was replaced with fresh medium supplemented
with 6 mg ml21 puromycin, and samples collected for analysis
24 h later (i.e. 48 h post-transfection).
5.6. CPC functional assay
Coverslips were harvested, paraformaldehyde fixed, stained
with rhodamine phalloidin (Life technologies) and mounted
using Vectashield with DAPI (Vector Labs). Coverslips were
scored visually on anAxioplan2microscope using a PlanNEO-
FLUAR 40/1,3 Oil objective (both Zeiss). Whole fields of
view were scored for the frequency of cells with normal and
abnormal (i.e. multinucleated, micronucleated and cells with
chromatin bridges) nuclei for greater than or equal to 1000
cells. During library screening, to control for any fluctuation
in background ANF, the ANF change for a given sample was
calculated as the raw ANF value divided by that of samples
transfected with empty pIRES puro2 vector in parallel on the
same day.
5.7. SICLOPPS processing assay
SICLOPPS construct expression andprocessingweremonitored
by western blot. Cells were recovered from experimentally
treated wells and lysed in 1 SDS-PAGE sample buffer.
Sampleswere resolved on a 10% SDS-PAGEgel and transferred
onto Hybond electrochemiluminescence (ECL) nitrocellulose
membrane (GE Healthcare) by wet transfer overnight at 48C
using a constant voltage of 30V. SICLOPPS expression and
processing products were detected by ECL or quantitative
(Li-Cor) western blotting.
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